Print this page
-
Screening Protocol for Clinical Trial Eligibility.
Protocol: 192101Principal Investigator:
- Christian Hinrichs (Rutgers University)
Applicable Disease Sites: Any Site -
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects.
Protocol: 192001Principal Investigator:
- Christian Hinrichs (Rutgers University)
Applicable Disease Sites: Any Site -
An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors.
Protocol: 052203Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.
Protocol: 072213Principal Investigator:
- Sharon Li (Rutgers University)
Applicable Disease Sites: Liver -
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Liver -
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT).
Protocol: 111806Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Liver
- 1
- 2